Novo Nordisk shares slumped on Monday after the drugmaker said the pill version of its weight-loss drug Ozempic had failed to slow the progression of Alzheimer’s disease in two large studies.
The Danish company said patients who took the drug did not see their disease progress more slowly, dashing hopes for a new use for the blockbuster diabetes drug.
Shares in Novo, which are listed in Copenhagen, dropped by more than 10% in early trading on Monday before easing back to close 5.8% down.
The pharmaceutical company has grown to be one of the biggest in Europe on the back of the success of its semaglutide-based drugs, Ozempic and weight-loss jab Wegovy. But it has lost more than half its value this year amid concerns that it cannot win back its early lead in the market.
Studies had previously suggested the rate of dementia was lower in people with type 2 diabetes who take drugs such as semaglutide, compared with those given a placebo.
Alzheimer’s, a progressive disease that can bring memory loss, language problems and personality change, is a difficult area of drug development and Novo had previously described the trials as a “lottery ticket”.
Novo’s trials, which enrolled nearly 4,000 patients, did not “translate into a delay of disease progression”, even as it “resulted in improvement of Alzheimer’s disease-related markers”, it said.
Martin Holst Lange, the Novo Nordisk chief scientific officer, said based on the “significant unmet need”, the company felt it “had a responsibility to explore semaglutide’s potential, despite a low likelihood of success”.
The Danish group has fallen behind its US competitor Eli Lilly, which last week became the first drugmaker to reach a $1tn market value in the US. The company has developed tirzepatide, marketed as Mounjaro, for type 2 diabetes and Zepbound for obesity.
The rivals are racing against each other to get an anti-obesity pill to market. While anti-obesity jabs, which mimic a gut hormone called GLP-1, have been explored in popularity in recent years, they are very expensive.
Pill versions are easier to store, distribute and administer and are expected to be cheaper, paving the way for millions more people to lose weight at a time when obesity is increasing around the world.
Securing the first weight-loss pill on the market will be critical for Mike Doustdar, who was appointed chief executive of Novo Nordisk this summer after his predecessor, Lars Fruergaard Jørgensen, was ousted over concerns the company was losing its dominance in the field.
In September, Doustdar announced that the company would cut 11% of its 78,400 global workforce in an effort to cut costs. This month, it trimmed its sales forecast for the fourth time this year because of a lag in sales of Wegovy and Ozempic.
A separate small study published at the Alzheimer’s Association international conference last year found that liraglutide – the GLP-1 analogue in another one of Novo’s other weight-loss treatments, Saxenda – appeared to help slow the loss of brain volume in people with Alzheimer’s disease.
